Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis by Sarah R. Donaldson, Andrew Radley, John F. Dillon

Subjects: Get full text

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study by T. Berg, P. Buggisch, D. Hueppe, S. Mauss, H. Wedemeyer, G. Teuber, T. Lutz, K. Stein, S. Wegner, H. Hinrichsen

Subjects: Get full text

Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study by Ying Chen, Yun Bao, Mengxia Yan, Huajie Jin, Kaijie Yao, Chi Zhang, Wen Li, Bin Wu

Subjects: Get full text

Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients by Juferdy Kurniawan, Anugrah Dwi Handayu, Gita Aprilicia, Darlene Raudhatul Bahri, Irsan Hasan

Subjects: Get full text

Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents by Zhang Y, Xia H, Fan L, Jiang L, Yang B, Wang F

Subjects: Get full text

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy by Xiping Ran, Xiping Ran, Yang Xu, Ying Wang, Cheng Zeng, Chen Gong, Ni Wang, Dachuan Cai, Dachuan Cai

Subjects: Get full text

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy by M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin

Subjects: Get full text

Residual HCV-RNA and Elevated Platelet-to-Lymphocyte Ratio Predict Poor Long-Term Outcomes in Patients with Chronic Hepatitis C After Treatment by Anna Wróblewska, Mateusz Gliwiński, Magda Rybicka, Małgorzata Cheba, Beata Lorenc, Piotr Trzonkowski, Krzysztof P. Bielawski, Katarzyna Sikorska

Subjects: “…Directly-acting antivirals…”
Get full text